Notch Therapeutics
Toronto
About Notch Therapeutics
Notch develops immune cell therapy developing a next-generation pipeline that is compatible and focuses on initial cancer cells. The company's proprietary T-cell production platform enables precision control of Notch signaling, which is required for T-cell development, by combining sophisticated product design with commercial-compatible processes. The ability to control notch signaling eliminates several critical limiting factors in cell therapy development and provides the ability to design and manufacture a consistent and limitless supply of therapeutic T cells. Notch Therapeutics was established in 2018 and is headquartered in Toronto, Canada.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $101.5M
- Last round: Series Unknown (Jun 2024)
- Website: notchtx.com
Industries & Categories
Biotechnology, Developer Platform, Health Care
Social Profiles
Canonical: https://fsome.com/organization/notch-therapeutics-93080 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.